Eurofound's EU PolicyWatch collates information on the responses of government and social partners to the COVID-19 crisis, the war in Ukraine, rising inflation, as well as gathering examples of company practices aimed at mitigating the social and economic impacts.
Factsheet for measure IT-2021-13/1845 – measures in Italy
|Country||Italy , applies nationwide|
|Time period||Open ended, started on 23 March 2021|
|Type||Legislations or other statutory regulations|
Reorientation of business activities
– Change of production/innovation
|Author||Lisa Dorigatti (University of Milan) and Eurofound|
|Measure added||11 April 2021 (updated 10 May 2021)|
In order to enhance research in and the industrial reconversion of the biopharmaceutical sector towards the production of new drugs and vaccines for emerging and widespread infectious diseases, Law Decree No. 41 of 22 March 2021 set up a specific fund with a total budget of €200 million for the year 2021.
The fund set up by Law Decree No. 41 of 22 March 2021, will grant financial concessions in support of private investments in the biopharmaceutical sector aiming at the production of new drugs and vaccines to deal with newly emerging infectious diseases at national level. The fund will support companies in the enhancement of their research investments in the mentioned sector and in their process of industrial reconversion, also through the creation of highly specialised poles, and the implementation of complementary and functional interventions by private companies. The total budget of the initiative amounts to €200 million for the year 2021.
Not yet available.
|Does not apply to workers||
Sector specific set of companies
||Does not apply to citizens|
Social partners' role in designing the measure and form of involvement:
|Trade unions||Employers' organisations|
|Role||No involvement||No involvement|
|Form||Not applicable||Not applicable|
Social partners' role in the implementation, monitoring and assessment phase:
No involvement in the definition of the measure.
No information available.
This case is sector-specific (only private sector)
|Economic area||Sector (NACE level 2)|
|C - Manufacturing||C21 Manufacture of basic pharmaceutical products and pharmaceutical preparations|
This case is not occupation-specific.
Eurofound (2021), Fund for enhancing research and the industrial reconversion of the biopharmaceutical sector, measure IT-2021-13/1845 (measures in Italy), EU PolicyWatch, Dublin, https://static.eurofound.europa.eu/covid19db/cases/IT-2021-13_1845.html
30 January 2023
Governments across the EU continue to implement policies to support citizens and businesses in the face of rising food and energy prices caused by the COVID-19 crisis and intensified by the war in Ukraine. This article summarises the policy responses as reported in Eurofound's EU PolicyWatch database from January to September 2022.Article
12 September 2022
Although the worldwide pandemic situation had already disrupted supply chains and triggered increases in energy and food prices in 2021, the situation deteriorated in 2022 with the Russian invasion of Ukraine.Article
12 September 2022
This article summarises the first policy responses that governments across the EU have started to implement to support companies affected by the rising prices, and those with commercial ties to Ukraine, Russia or Belarus.Article
5 July 2022
This article summarises the first policy responses of EU Member States, including those of the social partners and other civil society actors, enabling refugees to exercise their rights under the Temporary Protection Directive.Article
Disclaimer: This information has not been subject to the full Eurofound evaluation, editorial and publication process.